Carfilzomib Export Market Intelligence: India's 65 Suppliers Shipping to 47 Countries — TransData Nexus 2026

Q: Who are the top carfilzomib exporters from India?

The top carfilzomib exporters from India are: 1. MSN LABORATORIES PRIVATE LIMITED — $90.9K (7.5% market share); 2. SARTAJ PHARMA PRIVATE LIMITED — $32.9K (2.7% market share); 3. NATCO PHARMA LIMITED — $31.8K (2.6% market share); 4. 3S CORPORATION — $26.4K (2.2% market share); 5. RGSK CANADA HEALTHCARE INC. — $25.7K (2.1% market share). Together they account for 17.1% of India's total carfilzomib export value.

Q: What is the total export value of carfilzomib from India?

The total export value of carfilzomib from India is $1.2M USD, recorded across 203 shipment transactions from 65 active exporters to 47 destination countries. The average shipment value is $6.0K.

Q: Which countries import carfilzomib from India?

India exports carfilzomib to 47 countries worldwide. The top importing countries are: RUSSIA (60.7% share, $737.1K), CHILE (7.4% share, $89.7K), ECUADOR (4.4% share, $53.3K), UNITED ARAB EMIRATES (4.0% share, $48.9K), ARMENIA (3.5% share, $43.1K). These five markets account for 80.1% of total export value.

Q: What is the HS code for carfilzomib exports from India?

The primary HS code for carfilzomib exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of carfilzomib exports from India?

The average unit price for carfilzomib exports from India is $91.92 USD per unit, with prices ranging from $0.05 to $896.86 depending on formulation, packaging, and order volume. The total market is valued at $1.2M across 203 shipments.

Q: Which ports handle carfilzomib exports from India?

The primary ports for carfilzomib exports from India are SAHAR AIR (18.7% of shipments), SAHAR AIR CARGO ACC (INBOM4) (15.8% of shipments), DELHI AIR (12.8% of shipments), HYDERABAD ACC (INHYD4) (9.4% of shipments), Bombay Air (9.4% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of carfilzomib?

India is one of the world's leading exporters of carfilzomib due to its large base of 65 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports carfilzomib to 47 countries, demonstrating 24% global market coverage.

Q: What certifications do Indian carfilzomib exporters need?

Indian carfilzomib exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import carfilzomib from India?

There are 105 registered buyers importing carfilzomib from India, spread across 47 countries. The repeat buyer rate is 36.2%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top carfilzomib supplier from India?

MSN LABORATORIES PRIVATE LIMITED is the leading carfilzomib exporter from India with a market share of 7.5% and total export value of $90.9K across 19 shipments. The top 5 suppliers together control 17.1% of total export value.

Suresh Sormare

Carfilzomib

India Pharmaceutical Trade Intelligence

$1.2M65 Suppliers47 CountriesHS 30049049

ExportsIndia → RUSSIA60.7%India → CHILE7.4%

ImportsIRELAND → India$9.4M CANADA → India$518.8K

#1 Supplier: MSN LABORATORIES

Carfilzomib Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Carfilzomib to the World

Between 2022 and 2026, India exported $1.2M worth of carfilzomib across 203 verified shipments to 47 countries — covering 24% of world markets in the Advanced Oncology segment. The largest destination is RUSSIA (60.7%). MSN LABORATORIES PRIVATE LIMITED leads with a 7.5% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Carfilzomib export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Carfilzomib export data snapshot — $1.2M · 65 exporters · 47 countriesTransData Nexus · Indian Customs Data

Top Carfilzomib Exporters from India

65 active exporters · Ranked by export value

View all 65 →

Top Carfilzomib Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	MSN LABORATORIES PRIVATE LIMITED	$90.9K	19	4	7.5%
2	SARTAJ PHARMA PRIVATE LIMITED

Top Countries Importing Carfilzomib from India

47 destination markets · Ranked by import value

All 47 countries →

Top Countries Importing Carfilzomib from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	RUSSIA	$737.1K	60.7%
2	CHILE	$89.7K	7.4%
3	ECUADOR	$53.3K	4.4%
4	UNITED ARAB EMIRATES	$48.9K	4.0%
5	ARMENIA	$43.1K	3.5%
6	KENYA	$32.2K	2.7%
7	NEPAL	$25.0K	2.1%
8	BRAZIL	$22.3K	1.8%
9	JAMAICA	$16.5K	1.4%
10	AFGHANISTAN	$16.0K	1.3%

RUSSIA is India's largest carfilzomib export destination, absorbing 60.7% of total exports worth $737.1K. The top 5 importing countries — RUSSIA, CHILE, ECUADOR, UNITED ARAB EMIRATES, ARMENIA — together account for 80.1% of India's total carfilzomib export value. The remaining 42 destination countries collectively receive the other 19.9%, indicating a focused distribution strategy targeting key markets.

Who Supplies Carfilzomib to India?

15 origin countries · Total import value: $11.2M

India imports carfilzomib from 15 countries with a combined import value of $11.2M. The largest supplier is IRELAND ($9.4M, 6 shipments), followed by CANADA and UNITED STATES. All values are from Indian Customs (DGFT) import records.

Countries Supplying Carfilzomib to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	IRELAND	$9.4M	6	84.3%
2	CANADA	$518.8K	17	4.7%
3	UNITED STATES	$352.3K	29	3.2%
4	PUERTO RICO	$265.4K	4	2.4%
5	SINGAPORE	$173.4K	7	1.6%
6	SWITZERLAND	$93.7K	1	0.8%
7	BELGIUM	$85.5K	6	0.8%
8	UNITED ARAB EMIRATES	$59.4K	6	0.5%
9	UNITED KINGDOM	$46.9K	4	0.4%
10	GERMANY	$44.6K	3	0.4%

Showing top 10 of 15 origin countries

IRELAND is the largest supplier of carfilzomib to India, accounting for 84.3% of total import value. The top 5 origin countries — IRELAND, CANADA, UNITED STATES, PUERTO RICO, SINGAPORE — together supply 96.0% of India's carfilzomib imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Carfilzomib

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

As of March 2026, the FDA's Orange Book does not list any approved Abbreviated New Drug Applications (ANDAs) for carfilzomib, indicating the absence of generic versions in the U.S. market. The reference listed drug, Kyprolis (carfilzomib), received FDA approval on July 20, 2012. The regulatory pathway for carfilzomib involves a New Drug Application (NDA) submission, requiring comprehensive clinical data to demonstrate safety and efficacy. Given the absence of approved ANDAs, Indian exporters face limited opportunities in the U.S. market for generic carfilzomib. Additionally, the FDA's import alerts database does not currently list any alerts related to carfilzomib, suggesting no significant compliance issues for this product.

2EU & UK Regulatory Framework

In the European Union, the European Medicines Agency (EMA) granted marketing authorization for Kyprolis (carfilzomib) on November 19, 2015. The authorization covers its use in combination therapies for adult patients with multiple myeloma who have received at least one prior therapy. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has adopted similar regulatory standards post-Brexit, ensuring continued access to carfilzomib. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting to these markets, necessitating rigorous quality assurance processes.

3WHO Essential Medicines & Global Standards

As of the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, carfilzomib is not included. This exclusion may influence procurement decisions in countries that rely on the WHO list for their national formularies. Regarding pharmacopoeial standards, carfilzomib is not currently monographed in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), or Indian Pharmacopoeia (IP), which may impact quality control and regulatory assessments in various jurisdictions.

4India Regulatory Classification

In India, carfilzomib is classified under Schedule H of the Drugs and Cosmetics Rules, 1945, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for carfilzomib, allowing market-driven pricing. For export purposes, the Central Drugs Standard Control Organization (CDSCO) requires a No Objection Certificate (NOC), ensuring compliance with regulatory standards and monitoring of pharmaceutical exports.

5Patent & Exclusivity Status

Carfilzomib's primary patents have expired, opening the market to generic competition. However, the absence of approved ANDAs in the U.S. and limited marketing authorizations for generics in other regions suggest that generic versions are not yet widely available. This scenario presents an opportunity for Indian manufacturers to enter markets with high demand for cost-effective multiple myeloma treatments.

6Recent Industry Developments

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines. The 24th edition, published in September 2025, did not include carfilzomib, potentially affecting its adoption in national formularies. In April 2025, the EMA updated the product information for Kyprolis, reflecting new safety data and usage guidelines. In January 2026, the FDA issued guidance on the development of generic versions of complex drugs, including proteasome inhibitors like carfilzomib, aiming to facilitate the approval process for generics. In February 2026, the NPPA initiated a review of high-cost oncology drugs, including carfilzomib, to assess the need for price regulation. In March 2026, the CDSCO streamlined the export NOC process for pharmaceuticals, reducing approval times for exporters.

These developments underscore the dynamic regulatory environment affecting carfilzomib's global market presence and highlight opportunities for Indian exporters to navigate and capitalize on emerging trends.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Carfilzomib

Retail & reference prices across 9 markets vs. India FOB export price of $91.92/unit

Global Price Benchmark for Carfilzomib across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$2,500	USD	According to the FDA's Orange Book, Carfilzomib is approved for use in the United States.
United Kingdom	$2,340	GBP	The NHS Drug Tariff lists Carfilzomib as an approved medication.
Germany	$2,420	EUR	The European Medicines Agency (EMA) has authorized the use of Carfilzomib in Germany.
Australia	$2,100	AUD

Supply Chain Risk Assessment — Carfilzomib

API sourcing, concentration risk, storage requirements, and current alerts

MEDIUM RISK

1API Sourcing & Raw Material Dependency

Carfilzomib, a proteasome inhibitor used in multiple myeloma treatment, relies on complex Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). India, a significant producer of APIs, has historically depended heavily on China for KSMs, with imports accounting for over 70% of its bulk drug requirements. This dependency poses risks, as any disruption in Chinese supply chains can directly impact Indian pharmaceutical manufacturing. For instance, in July 2025, geopolitical tensions led to temporary export restrictions from China, causing delays in API production in India.

To mitigate such vulnerabilities, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Bulk Drugs, launched in July 2020. By September 2025, this initiative had established domestic production capacities for 26 KSMs and APIs, reducing import reliance and enhancing supply chain resilience. However, the effectiveness of these measures in fully addressing the dependency on Chinese KSMs remains to be seen, especially for specialized compounds like those used in Carfilzomib.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data from 2022 to 2026 indicates that the top five exporters of Carfilzomib from India account for 17.1% of total exports, with MSN Laboratories Private Limited leading at a 7.5% share. This relatively low concentration suggests a diversified supplier base, which can mitigate risks associated with over-reliance on a single source. However, the presence of 65 active exporters also implies potential variability in quality and supply consistency.

Access Complete Carfilzomib Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 203 transactions across 47 markets.

Request Demo View Pricing

Frequently Asked Questions — Carfilzomib Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top carfilzomib exporters from India?

The leading carfilzomib exporters from India are MSN LABORATORIES PRIVATE LIMITED, SARTAJ PHARMA PRIVATE LIMITED, NATCO PHARMA LIMITED, and 7 others. MSN LABORATORIES PRIVATE LIMITED leads with 7.5% market share ($90.9K). The top 5 suppliers together control 17.1% of total export value.

What is the total export value of carfilzomib from India?

The total export value of carfilzomib from India is $1.2M, recorded across 203 shipments from 65 active exporters to 47 countries. The average shipment value is $6.0K.

Which countries import carfilzomib from India?

India exports carfilzomib to 47 countries. The top importing countries are RUSSIA (60.7%), CHILE (7.4%), ECUADOR (4.4%), UNITED ARAB EMIRATES (4.0%), ARMENIA (3.5%), which together account for 80.1% of total export value.

What is the HS code for carfilzomib exports from India?

The primary HS code for carfilzomib exports from India is 30049049. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Carfilzomib

Carfilzomib

Top Carfilzomib Exporters from India

Top Countries Importing Carfilzomib from India

Who Supplies Carfilzomib to India?

Quick Facts

Related Advanced Oncology

Related Analysis

Need Details?

Regulatory Landscape — Carfilzomib

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Carfilzomib

Supply Chain Risk Assessment — Carfilzomib

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Carfilzomib Trade Intelligence

Frequently Asked Questions — Carfilzomib Exports from India

Who are the top carfilzomib exporters from India?

What is the total export value of carfilzomib from India?

Which countries import carfilzomib from India?

What is the HS code for carfilzomib exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of carfilzomib exports from India?

Which ports handle carfilzomib exports from India?

Why is India a leading exporter of carfilzomib?

What certifications do Indian carfilzomib exporters need?

How many buyers import carfilzomib from India?

What is the market share of the top carfilzomib exporter from India?

Analysis Methodology